Association of aortic valve calcification and vitamin K antagonist treatment
| Autor: | Abdel Monem Kikar, Selma Hasific, Martin Busk, Jesper Hallas, and Axel Diederichsen, Oke Gerke, Flemming Hald Steffensen, Pernille Stegemejer Sønderskov, Marek Karon, Grazina Urbonaviciene, Jess Lambrechtsen, Lars Melholt Rasmussen, J. S. Lindholt, Lars Frost |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Male
medicine.medical_specialty Vitamin K Statin medicine.drug_class Population new oral anticoagulants Administration Oral aortic valve calcification 030204 cardiovascular system & hematology Vitamin k State Medicine vitamin K 03 medical and health sciences 0302 clinical medicine Internal medicine Atrial Fibrillation Humans Medicine risk factors Radiology Nuclear Medicine and imaging Anticoagulant use 030212 general & internal medicine education cardiac CT scan education.field_of_study business.industry Confounding Anticoagulants General Medicine Vitamin K antagonist Confidence interval vitamin K antagonists Aortic Valve Female Aortic valve calcification Cardiology and Cardiovascular Medicine business |
| Zdroj: | Sønderskov, P S, Lindholt, J S, Hallas, J, Gerke, O, Hasific, S, Lambrechtsen, J, Steffensen, F H, Busk, M, Frost, L, Urbonaviciene, G, Karon, M, Kikar, A M, Rasmussen, L M & Diederichsen, A 2020, ' Association of aortic valve calcification and vitamin K antagonist treatment ', European Heart Journal Cardiovascular Imaging, vol. 21, no. 7, pp. 718-724 . https://doi.org/10.1093/ehjci/jeaa065 Sønderskov, P S, Lindholt, J S, Hallas, J, Gerke, O, Hasific, S, Lambrechtsen, J, Steffensen, F H, Busk, M, Frost, L, Urbonaviciene, G, Karon, M, Kikar, A M, Rasmussen, L M & Diederichsen, A A 2020, ' Association of aortic valve calcification and vitamin K antagonist treatment ', European Heart Journal Cardiovascular Imaging, vol. 21, no. 7, pp. 718-724 . https://doi.org/10.1093/ehjci/jeaa065 |
| DOI: | 10.1093/ehjci/jeaa065 |
| Popis: | Aims Vitamin K antagonists (VKAs) are suspected of causing aortic valve calcification (AVC). The objective of this study was to clarify whether patients undergoing VKA treatment have increased AVC scores compared to patients treated with new oral anticoagulants (NOACs) and patients who never have been treated with VKA/NOAC. Methods and results We included participants from the population-based DANCAVAS trial (n = 15 048). Information on confounders was collected, and the AVC scores were measured on non-contrast computed tomography scans. The participants’ medication data, including VKA and NOAC data, were collected from the Danish National Health Service Prescription Database. The final population consisted of 14 604 participants (67.4 years, 95% men) of whom 873 had been treated with VKA and 602 with NOAC. The association between AVC score and duration of anticoagulant use was investigated in an adjusted zero-inflated negative binomial regression model. For every year treated with VKA, the AVC score increased, on average, by 6% [ratio of expected counts (RECs) = 1.06; 95% confidence interval (CI) 1.02–1.10] compared to non-use. The results were consistent in sensitivity analyses excluding patients with known cardiovascular disease and statin users (REC = 1.07; 95% CI 1.02–1.11 and REC = 1.10; 95% CI 1.03–1.17, respectively). NOAC treatment was not significantly associated with AVC score in any of the corresponding models (REC = 1.03, 1.02, and 0.96). Conclusion Compared to no treatment with anticoagulants, VKA use was associated with increased AVC score, while a similar association could not be established for NOAC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|